Clinical trials located in

Olomouc

Olomouc city is located in Czechia. Currently, 20 clinical trials are being conducted in this city.

Olomouc, nestled in the Moravian region of Czechia, boasts a rich history dating back to the Roman Empire. This city is renowned for its stunning baroque architecture, including the Holy Trinity Column, a UNESCO World Heritage site. Olomouc is also home to the second-largest historic preservation zone in the Czech Republic, showcasing a blend of architectural styles. The city’s vibrant cultural scene is anchored by Palacký University, one of the oldest universities in Central Europe. Olomouc’s astronomical clock, a rare socialist-realist artifact, is a unique feature, contrasting with the city’s predominantly historical ambiance.

  • CT-EU-00118816

    Study on the safety and effectiveness of Setanaxib for Alport Syndrome patients

    The purpose of this study is to learn about the safety and tolerability of a drug called setanaxib in patients with Alport syndrome, when added to their standard of care treatment. The study will compare how safe setanaxib is when compared to a placebo. Participants will be asked about any side effects they experience at each study visit. Additionally, tests in blood, urine, and other examinations will be used to assess the safety of setanaxib. The study will also measure how well setanaxib works in comparison to a placebo by measuring urine protein and certain markers in the blood and urine. The concentration of setanaxib in the blood will also be measured throughout the course of the study.

    This is a Phase 2a, randomized, double-blind, placebo-controlled study. This means that participants will be randomly assigned to receive either setanaxib or a placebo, and neither the participants nor the researchers will know who is receiving which treatment.

    • placebo
    • Setanaxib
  • Baricitinib study in children with juvenile idiopathic arthritis

    This clinical trial is designed to test whether Baricitinib is safe and effective in the treatment of systemic juvenile idiopathic arthritis in children aged 1 to 18 years. Participants will be assigned to one of two groups. In the first group, some participants will receive Baricitinib and others Tocilizumab as the reference drug. In the second group, all participants will receive Baricitinib.

    The primary objective of the study is to evaluate the percentage of participants who experience at least a 30% improvement in disease symptoms after 12 weeks of treatment according to the modified American College of Rheumatology Pediatric Response Criteria (PediACR30). Baricitinib is administered orally and Tocilizumab is administered by subcutaneous injection.

    • Tocilizumab
    • baricitinib
  • To evaluate a combination of 3 different drugs versus 2 other drugs in the treatment of patients with melanoma

    This study compares two different approaches to treating advanced melanoma, a type of skin cancer that has spread to other parts of the body. This study is specifically aimed at patients with a gene mutation called BRAF who have previously received treatment with drugs such as nivolumab or pembrolizumab.

    One therapeutic approach involves taking three study drugs: pembrolizumab administered intravenously every 3 weeks, along with encorafenib and binimetinib taken orally daily at home. The second approach involves taking two study drugs: ipilimumab and nivolumab administered intravenously every 3 weeks for the first 4 doses, followed by nivolumab alone every 4 weeks. Both treatments will last for approximately 2 years, but there is no time limit for treatment with encorafenib and binimetinib.

    The research team will closely monitor the patients’ health during regular clinic visits to see how they are responding to treatment. The main goal is to determine which treatment method is more effective in shrinking or eliminating melanoma tumors.

    • Nivolumab
    • Ipilimumab
    • Binimetinib
    • Encorafenib
    • Pembrolizumab
  • To evaluate the effectiveness of nivolumab used alone and in combination with HBI-8000 in the treatment of unresectable or metastatic melanoma

    This is a study comparing two treatment options for patients with melanoma that cannot be surgically removed or has spread to other parts of the body. One treatment option is an investigational drug called Tucidinostat (HBI-8000) taken by mouth twice a week in combination with an approved drug called nivolumab given by intravenous infusion. Another option is a placebo taken orally twice a week, also in combination with nivolumab given by intravenous infusion.

    The primary goal of the study is to determine whether the combination of HBI-8000 and nivolumab is more effective than nivolumab alone in shrinking the tumor or preventing further tumor progression. The study will also assess the safety of the treatment combinations.

    Patients enrolled in the main study will be randomly assigned to receive either the HBI-8000 combination or a placebo combination. Treatment will continue for up to 2 years or until the cancer progresses, side effects worsen or the patient decides to withdraw from the study. The study will last up to 4 years and will include regular monitoring and follow-up visits.

    • Placebo
    • Tudicdinostat/HBI-8000
  • Studying efficacy of volrustomig for metastatic lung cancer

    The study compared two treatments for metastatic non-small cell lung cancer: volrustomig with chemotherapy and pembrolizumab with chemotherapy. Its purpose is to determine which combination is more effective and safer. Patients will be divided into two groups. One group will receive volrustomig and chemotherapy, and the other group will receive pembrolizumab and chemotherapy. The effectiveness of treatment in each group will then be tracked using imaging tests. In addition, a group of researchers will follow each participant until the end of the study to make sure the treatment is safe and tolerable.

    • Volrustomig
    • Pemetrexed
    • Carboplatin
    • Pembrolizumab
    • Paclitaxel
  • Investigating new treatment method for specific head and neck squamous cell carcinoma

    This clinical trial is focused on evaluating the safety and efficacy of a new treatment for patients with a specific type of head and neck cancer caused by Human Papilloma Virus 16 (HPV16) and characterized by the presence of the PD-L1 protein. The treatment involves a combination of a novel drug, BNT113, and a known drug, pembrolizumab. The primary objective is to determine whether this combination is more effective than pembrolizumab alone in assisting the body’s immune system in fighting the cancer. The trial is divided into two parts. In the initial phase, the focus is on assessing the safety of the new drug combination. Subsequently, in the second phase, patients will be randomly assigned to receive either the new combination or pembrolizumab alone. The trial aims to compare the outcomes of the two groups, evaluating tumor response (whether tumors shrink, remain the same, or grow) and monitoring any potential side effects resulting from the treatment.

    • BNT113
    • Pembrolizumab
  • Study investigating new medicine for advanced metastatic breast cancer

    A clinical study is investigating the impact and safety of a new medicine named ARV-471 (Vepdegrestrant), contrasting its effects with an already-used drug called fulvestrant (FUL). This research targets individuals suffering from advanced metastatic breast cancer, a disease that often spreads to various parts of the body and is challenging to control. ARV-471 will be given to half of the participants, with the other half receiving fulvestrant. The effects of both will be monitored over time. ARV-471 is consumed by mouth, while FUL is administered through injections.

    • Vepdegrestrant/ARV-471
    • Fulvestrant
  • Evaluating effects of pembrolizumab with chemotherapy and radiation for esophageal cancer

    This trial explores the impact of a drug called pembrolizumab on patients with a specific kind of cancer, Esophageal Carcinoma. It compares two treatments. Some patients will receive the standard treatment (chemotherapy and radiation), plus a placebo. Others will receive the standard treatment (chemotherapy and radiation) plus Pembrolizumab. The reason for doing it is to see if Pembrolizumab, when added to normal treatment, can help patients live without their cancer getting worse, or live longer overall. During the trial, patients will either be given pembrolizumab or placebo, as well as one of two chemotherapy combinations and radiation treatment, for about a year.

    • Pembrolizumab
    • levoleucovorin
    • leucovorin
    • 5-Fluorouracil
    • Cisplatin
    • Oxaliplatin
  • Emapalumab treatment study for patients with Macrophage Activation Syndrome

    This study is a test of a medicine called emapalumab on children and adults who have a condition called Macrophage Activation Syndrome (MAS), found in diseases like Still’s Disease or Systemic Lupus Erythematous. People who have not gotten better with high doses of a treatment called glucocorticoids may benefit from this study. The scientists want to understand if this medicine is safe, doesn’t cause too much discomfort, and if it works. The research will be done in two groups of people: Group 1 includes those with MAS from Still’s Disease, and Group 2 includes those with MAS from Systemic Lupus Erythematous. Scientists will track how the medicine behaves in the body, and the quality of life in these groups, for up to 1 year after the last dose of emapalumab.

    • Emapalumab
  • Comparing treatments in multiple myeloma: talquetamab in combination with other medication

    This study aims to explore the combined effects of talquetamab, daratumumab, pomalidomide, and dexamethasone for treating relapsed or refractory multiple myeloma. One group of patients will receive talquetamab subcutaneous in combination with daratumumab and pomalidomide. The second group will receive talquetamab subcutaneous in combination with daratumumab. The patients of the third group will be treated with daratumumab subcutaneous in combination with pomalidomide and dexamethasone. The research is divided into three phases: screening, treatment, and post-treatment follow-up. The study will assess efficacy, safety, and monitoring various health indicators at specific time points. The results of this combination therapy will be compared to choose the safest and the most effective treatment. The overall duration of the study is expected to be up to 6 years and 6 months.

    • Pomalidomide
    • Talquetamab
    • Dexamethasone
    • Daratumumab
  • Evaluating different drugs for advanced multiple myeloma

    This study is conducted to see how good a medication called Elranatamab is for individuals having multiple myeloma, a blood cancer that affects the marrow inside your bones. This study will use Elranatamab alone, or pair it with another medication called Daratumumab. The aim is to see if Elranatamab alone or mixed with Daratumumab is better than the current treatment of Daratumumab mixed with two other medications named Pomalidomide and Dexamethasone. This research is primarily for individuals who have undergone previous treatments with medications, Lenalidomide and a proteasome inhibitor. The study has two parts. The aim of the first part is the safety test and effects of Elranatamab mixed with Daratumumab at various doses. The second part will divide participants into three groups: Elranatamab alone, Elranatamab with Daratumumab, or the current treatment. The goal is to observe which treatment is safer and works better.

    • Elranatamab
    • Pomalidomide
    • Dexamethasone
    • Daratumumab
  • Continued study of ozanimod for severe Crohn’s Disease

    This research is about an extended study on the use of an oral medication named Ozanimod for people suffering from Crohn’s disease. Crohn’s disease can make the stomach and intestines really uncomfortable, causing swellings and pain. The main aim of this study is to check if this medicine, Ozanimod, is safe for intake and how effective it is in easing these uncomfortable feelings in the stomach. The researchers will rate patients’ illnesses using the Crohn’s Disease Activity Index (a measurement tool).

    • Ozanimod
  • Study of etrasimod in treating intense ulcerative colitis

    This study is a follow-up to previous research for the treatment of people with moderate to serious ulcerative colitis (UC). UC is a condition that inflames the large intestine and causes sores on the inside. The study will monitor the effects and safety of a medicine called etrasimod. This research is for people who have been part of past research trials and wish to continue treatment. Doctors will track a few things like side effects and how the medicine affects the disease in ways they have designed.

    • Etrasimod
  • Long-term study on the effectiveness of mirikizumab for Crohn’s Disease

    This research study is about a long-term test of a medicine called Mirikizumab for people who have Crohn’s disease. The main aim of this study is to know if the medicine is effective and safe for those people eventually. The effect of the medicine will be checked using different tests and scores like the Simple Endoscopic Score for Crohn’s Disease, the Crohn’s Disease Activity Index, and patient-reported outcomes. Researchers will also be checking changes in certain markers in the blood and stool that can show inflammation.

    • Mirikizumab
  • Inupadenant study in second-line non-small cell lung cancer

    This clinical trial aims to explore the potential of inupadenant (EOS100850) when combined with standard chemotherapy drugs, carboplatin and pemetrexed, in treating advanced non-small cell lung cancer in adults. The study is particularly focused on patients for whom previous immunotherapy treatments were not successful.

    The trial has two primary goals. Initially, it seeks to determine the most effective and safest dose of inupadenant when used alongside chemotherapy. Once the optimal dosage is established, the next phase involves comparing the treatment’s effectiveness against a placebo, in combination with the chemotherapy drugs.

    Throughout the study, participants’ health and responses to the treatment are closely monitored.

    • inupadenant
    • Pemetrexed
    • Carboplatin
  • Study of evorpacept in patients with advanced HER2+ gastric cancer

    This study will investigate the drug evorpacept (ALX148). The clinical trial consists of two phases and includes patients with advanced stomach or gastroesophageal junction (GEJ) cancer showing excessive HER2 receptor expression. The study focuses on patients whose disease did not respond to prior HER2-directed therapy and chemotherapy containing fluoropyrimidine or platinum. Patients participating in the study will be closely monitored to see how well the cancer responds to the treatment and to track any side effects they might experience. By looking at these results, researchers hope to find out if this new combination can offer a more effective treatment option for patients with this type of advanced gastric cancer, potentially leading to better management of the disease and improved survival rates.

    • Evorpacept/ALX148
    • Ramucirumab
    • Trastuzumab
    • Paclitaxel
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Testing bemarituzumab treatment on solid tumors

    This study is testing a new drug, bemarituzumab, for people with certain advanced solid tumors that are high in a protein called FGFR2b. It is for adults whose cancer has not responded to previous treatment or cannot be surgically removed. The main goal of this test is to see if bemarituzumab can help fight these cancers and to make sure it is safe for people to take. Participants receive the drug through a drip. This study will use special imaging methods, such as computed tomography or magnetic resonance imaging, to see how the tumors respond to the drug. If the drug helps and the tumor shrinks or doesn’t grow, researchers will track how long it lasts.

    • Bemarituzumab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Evaluating two drug combinations for advanced breast cancer

    This study is examining two different drug combinations for treating a specific type of breast cancer. The primary aim is to assess the comparative effectiveness and safety of these combinations. One combination uses the drugs lasofoxifene and abemaciclib, and the other uses fulvestrant and abemaciclib. The patients for this trial are men and women who have already been treated for breast cancer that has spread or cannot be removed by surgery, is positive for estrogen receptors (ER+), does not over-produce a growth factor (HER2-), and has a specific genetic mutation (ESR1).

    • Fulvestrant
    • Abemaciclib
    • Lasofoxifene

See more clinical trials in other cities in Czechia:

.